How well does Yervoyg(Ipilimumab) work?

YERVOY is indicated for a range of advanced malignancies, offering clinical benefit through immune checkpoint inhibition.

Therapeutic Efficacy of YERVOY in Oncology

YERVOY (ipilimumab) is approved for the treatment of unresectable or metastatic melanoma, adjuvant therapy in melanoma with lymph node involvement, advanced renal cell carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell carcinoma. 

Its mechanism involves CTLA-4 blockade, enhancing T-cell mediated antitumor responses. Clinical trials have demonstrated improved survival and durable responses in these indications, particularly when used in combination with nivolumab.